RESULTS OF THE ANALYSIS OF THE ASSOCIATION OF GENETIC POLYMORPHISM IN LIPID-LOWERING THERAPY IN PATIENTS WITH TYPE 2 DIABETES MELLITUS

View at publisher Summarise with VIRAT
Authors: A. A. Mosinа
Cited by: 0
References: 19

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Diabetes mellitus (DM) is one of the most common pathologies worldwide. According to the federal register, almost 3% of the total population of the Russian Federation suffers from this disease. Type 2 diabetes mellitus (DM2) has a high prevalence as a multifactorial disease. The course of the disease itself is significantly complicated by the presence of concomitant pathologies: arterial hypertension (AH), coronary artery disease (CHD), chronic heart failure (CHF), dyscirculatory encephalopathy (DE), bronchial asthma (BA), chronic obstructive pulmonary disease (COPD), etc. Atherosclerosis occupies a special place among comorbidities, the progression of which significantly increases the risk of diabetic complications. DM2 and atherosclerosis have a relationship, since the development and further aggravation of endothelial dysfunction is observed in both pathologies. Many factors contribute to the increase in concentrations of low-density lipoproteins (LDL), very low-density lipoproteins (VLDL), cholesterol (CL), triglycerides (TG): bad habits (smoking and regular intake of alcoholic beverages), consumption of foods high in saturated fat, sedentary lifestyle, chronic stress and systemic inflammation. The presence of a genetic predisposition in the patient can be considered as a risk factor. There are a number of single nucleotide polymorphisms (SNPs) that increase the risk of atherosclerosis and its rapid progression. Among them, there is a mutation in the gene responsible for the work of endothelial nitric oxide synthase 3 (eNOS3). Patients with the C allele in their genotype are susceptible to developing endothelial dysfunction. Timely identification of the risk group and the appointment of optimal lipid-lowering therapy will significantly slow down the development of cardiovascular complications.

Fields of Study & Subjects

Lipoproteins and Cardiovascular Health Pharmacogenetics and Drug Metabolism Genetic Associations and Epidemiology

Publication details

Journal / source
Bulletin Biomedicine and sociology
Volume
11
Issue
01
Pages
46–46
Publication date
28 February 2026
Language
EN